Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim and ESAs in ESA-resistant Anemic Patients
NCT07854561Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in anemia of chronic kidney disease, sponsored by The Chinese University of Hong Kong. Primary endpoints: Incidence of platelet counts exceeding the normal range at 28 weeks, Proportion of patients maintaining platelet counts within the normal range at 28 weeks and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
romiplostim
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT07854561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854561.